Mesoblast’s Covid drug saves toddler
A four-year-old in the US battling complications from COVID-19 wasn’t responding well until his doctor turned to an experimental Australian drug.
A four-year-old in the US battling complications from COVID-19 wasn’t responding well until his doctor turned to an experimental Australian drug.
As unemployment surges towards 10 per cent, Vitalharvest’s managing director David Schwartz says there are jobs to be found.
A much-hyped law to name and shame big businesses to pay their smaller suppliers within 30 days has been labelled ineffective and “riddled with deficiencies”.
How do we ensure global coverage of a COVID-19 vaccine?
The first e-sports platform to go public in the US is growing fast and has ambitious plans to take on juggernauts Google and Facebook.
Pragmatism has trumped geopolitical fears on farms, with barley growers saying ‘we’ll sell to other markets’ after China banned their grain.
Australia Post senior executives, including CEO Christine Holgate, remain eligible for bonuses to be paid this month.
Chemicals company Nufarm has unveiled a $215m writedown of its European assets and warned of lower full-year earnings.
Weed contaminants ‘well within the tolerances’ accepted by Beijing and Canberra, CBH finds.
Is the $120k contract for PwC for the federal government’s payment reporting times framework a waste of money?
Original URL: https://www.theaustralian.com.au/author/jared-lynch/page/198